The drug was recently approved in the US for familial chylomicronaemia syndrome
News
FDA approves Amneal’s self-administered migraine drug Brekiya
Brekiya is now the first DHE auto-injector to be approved by the regulator
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis
Regulator confirms safety and efficacy of new treatment option for patient
Massalia Therapeutics launches to advance novel treatments for complex conditions
Biotech spin-off targets fibrosis, neoplasm and neovascularization
AviadoBio opens UK trial for FTD gene therapy
Aspire-FTD study aims to stop disease progression with one-time treatment
Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease
Trial progresses towards topline data expected later in the year
Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment
FDA recognises KER-0193 as a potential therapy for rare paediatric disease
Rein Therapeutics initiates renew phase 2 trial for IPF treatment
Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi
Apiary invests in life sciences marketing specialist performance-io
Private equity firm Apiary Capital backs rapid growth of performance-i
Amgen’s Tepezza granted marketing authorisation in the UK
Teprotumumab approved as first targeted treatment for thyroid eye disease
iOnctura starts randomised phase 1/2 trial in lung cancer treatment
Study explores whether PI3Kδ targeting could combat resistance
MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d
UCB’s developmental treatment may be eligible for patient access
PharmaTimes Clinical Researcher of the Year – The Americas Awards
Demonstrate your skill and prowess by entering this year’s awards!
Chiesi partners with Wirral Primary Care to improve COPD detection
New initiative aims to accelerate diagnosis and ease NHS pressures
Johnson & Johnson submits application for subcutaneous Rybrevant dosing
Company seeks approval for new schedules to improve patient convenience
